YK-4-279 can also target a subpopulation of chemoresistant ESFT stem cells [135] and it has been recently described as an effective antiinvasive agent in ETV1 and ERG fusion positive prostate tumors although the mechanism of action of YK-4-279 in prostate cancer cells seems to be different [136]. The gene discussed is ERG; the disease is prostate carcinoma.